Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline Review, H1 2015

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline Review, H1 2015', provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview 9

Therapeutics Development 10

Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Overview 10

Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Comparative Analysis 11

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Therapeutics under Development by Companies 12

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Products under Development by Companies 18

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Companies Involved in Therapeutics Development 20

Altor BioScience Corporation 20

Amgen Inc. 21

Astellas Pharma Inc. 22

AstraZeneca Plc 23

ATLAB Pharma SAS 24

BIND Therapeutics, Inc. 25

Boehringer Ingelheim GmbH 26

Boston Biomedical, Inc. 27

Eli Lilly and Company 28

Exelixis, Inc. 29

Incyte Corporation 30

Johnson & Johnson 31

Merck & Co., Inc. 32

Mirati Therapeutics Inc. 33

Novartis AG 34

Pfizer Inc. 35

Sanofi 36

Sumitomo Dainippon Pharma Co., Ltd. 37

Teva Pharmaceutical Industries Limited 38

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Target 40

Assessment by Mechanism of Action 43

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

AdIL-24-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

ALT-801-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

AMG-228-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

amrubicin hydrochloride-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

ATL-101-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

AZD-4547-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

B-701-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

BBI-503-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

buparlisib hydrochloride-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

cabazitaxel-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

cabozantinib s-malate-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

CEP-11981-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

docetaxel-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

enfortumab vedotin-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

epacadostat-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

JNJ-42756493-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

mitomycin-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

mocetinostat-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

nintedanib-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

palbociclib-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

pembrolizumab-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

ramucirumab-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

SAR-408701-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

vandetanib-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Recent Pipeline Updates 114

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Dormant Projects 163

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Discontinued Products 164

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Product Development Milestones 165

Featured News & Press Releases 165

May 13, 2015: Mirati Therapeutics to Provide Updates on Mocetinostat at 2015 ASCO Annual Meeting 165

May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 165

Appendix 167

Methodology 167

Coverage 167

Secondary Research 167

Primary Research 167

Expert Panel Validation 167

Contact Us 167

Disclaimer 168

List of Tables

Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H1 2015 10

Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Altor BioScience Corporation, H1 2015 20

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Amgen Inc., H1 2015 21

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Astellas Pharma Inc., H1 2015 22

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by AstraZeneca Plc, H1 2015 23

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by ATLAB Pharma SAS, H1 2015 24

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by BIND Therapeutics, Inc., H1 2015 25

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Boehringer Ingelheim GmbH, H1 2015 26

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Boston Biomedical, Inc., H1 2015 27

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Eli Lilly and Company, H1 2015 28

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Exelixis, Inc., H1 2015 29

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Incyte Corporation, H1 2015 30

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Johnson & Johnson, H1 2015 31

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Merck & Co., Inc., H1 2015 32

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Mirati Therapeutics Inc., H1 2015 33

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Novartis AG, H1 2015 34

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Pfizer Inc., H1 2015 35

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Sanofi, H1 2015 36

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 37

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 38

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Stage and Target, H1 2015 41

Number of Products by Stage and Mechanism of Action, H1 2015 44

Number of Products by Stage and Route of Administration, H1 2015 47

Number of Products by Stage and Molecule Type, H1 2015 49

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics-Recent Pipeline Updates, H1 2015 114

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Dormant Projects, H1 2015 163

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Discontinued Products, H1 2015 164

List of Figures

Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H1 2015 10

Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 16

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Top 10 Targets, H1 2015 40

Number of Products by Stage and Top 10 Targets, H1 2015 40

Number of Products by Top 10 Mechanism of Actions, H1 2015 43

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 43

Number of Products by Top 10 Routes of Administration, H1 2015 46

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 46

Number of Products by Top 10 Molecule Types, H1 2015 48

Number of Products by Stage and Top 10 Molecule Types, H1 2015 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Altor BioScience Corporation

Amgen Inc.

Astellas Pharma Inc.

AstraZeneca Plc

ATLAB Pharma SAS

BIND Therapeutics, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Eli Lilly and Company

Exelixis, Inc.

Incyte Corporation

Johnson & Johnson

Merck & Co., Inc.

Mirati Therapeutics Inc.

Novartis AG

Pfizer Inc.

Sanofi

Sumitomo Dainippon Pharma Co., Ltd.

Teva Pharmaceutical Industries Limited

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutic Products under Development, Key Players in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Pipeline Overview, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Pipeline, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com